A. Vuolanto

发表

Bioreactor for solid-state cultivation of Phlebiopsis gigantea

M. Leisola, V. Virtanen, A. Nyyssölä, 2008, Biotechnology Letters.

Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer

J. Karbach, K. Partanen, N. Linder, 2015, Oncoimmunology.

Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization

J. Karbach, K. Partanen, N. Linder, 2014, Oncoimmunology.

Cross-linked protein crystal technology in bioseparation and biocatalytic applications

Antti Vuolanto, A. Vuolanto, 2004 .

Enhanced Glucose to Fructose Conversion in Acetone with Xylose Isomerase Stabilized by Crystallization and Cross‐Linking

M. Leisola, A. Krause, K. Vilonen, 2004, Biotechnology progress.

C-2 Epimer Formation of Tetrose, Pentose and Hexose Sugars by Xylose Isomerase

H. Schoemaker, M. Leisola, A. Vuolanto, 2002 .

Enantioselective Affinity Chromatography of a Chiral Drug by Crystalline and Carrier‐Bound Antibody Fab Fragment

M. Leisola, J. Jokela, A. Vuolanto, 2004, Biotechnology progress.

Phase 1 Lymfactin® Study: 24-month Efficacy and Safety Results of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema.

K. Alitalo, S. Suominen, I. Kaartinen, 2022, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment

A. Hemminki, L. Vassilev, V. Cerullo, 2017, PloS one.

Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

J. Karbach, K. Partanen, N. Linder, 2016, Journal of Immunotherapy for Cancer.

Phytase production by high cell density culture of recombinant Bacillus subtilis

H. Ojamo, M. Leisola, A. Vuolanto, 2001, Biotechnology Letters.

Abstract OT1-06-01: Lymfactin, an investigational adenoviral gene therapy expressing VEGF-C, is currently studied in a double-blind, randomized, placebo-controlled, multicenter, phase 2 clinical study in patients suffering from breast cancer associated secondary lymphedema (BCAL)

A. Vuolanto, P. Hartiala, A. Saarikko, 2020 .

Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks

V. Cerullo, S. Pesonen, L. Kuryk, 2019, International journal of molecular sciences.